Early metabolic response assessment to neoadjuvant endocrine treatment in ER+, HER2-breast cancer: comparison to the morphological and pathological response

被引：0

作者：

Boughdad, Sarah ^{[1
]}

Champion, Laurence ^{[1
]}

Becette, Veronique ^{[2
]}

Cherel, Pascal ^{[2
]}

Mouret-Fourme, Emmanuelle ^{[2
]}

Edeline, Veronique ^{[1
]}

Lemonnier, Jerome ^{[3
]}

Lerebours, Florence ^{[2
]}

Alberini, Jean-Louis ^{[1
]}

机构：

[1] Ctr Rene Huguenin, Inst Curie, Nucl Med, St Cloud, France

[2] Ctr Rene Huguenin, Inst Curie, St Cloud, France

[3] Unicancer, Paris, France

来源：

JOURNAL OF NUCLEAR MEDICINE | 2015年 / 56卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

1311

引用

页数：1

共 50 条

[41] Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study
Bhargava, Rohit
Esposito, Nicole N.
O'Connor, Siobhan M.
Li, Zaibo
Turner, Bradley M.
Moisini, Ioana
Ranade, Aditi
Harris, Ronald P.
Miller, Dylan, V
Li, Xiaoxian
Moosavi, Harrison
Clark, Beth Z.
Brufsky, Adam M.
Dabbs, David J.
MODERN PATHOLOGY, 2021, 34 (01) : 77 - 84
[42] TMEM doorway score as a predictive biomarker for therapy selection in ER+/HER2-breast cancer
Parmar, Priyanka
Miller, Andrew
Karadal-Ferrena, Burcu
Shukla, Suryansh
Huang, Cien
Ginsberg, Mindy
Rosenbaum, Chedva
Felder, Malka
Zhang, Chenxin
Condeelis, John S.
Xue, Xiaonan
Rohan, Thomas E.
Sparano, Joseph A.
Anampa, Jesus D.
Entenberg, David
Oktay, Maja H.
CANCER RESEARCH, 2024, 84 (22)
[43] Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2-breast cancer
Martinez-Perez, Carlos
Turnbull, Arran K.
Kay, Charlene
Dixon, J. Michael
EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (01) : 67 - 86
[44] Comparison of oncological outcomes of premenopausal with ovarian function suppression versus postmenopausal women in ER+/HER2-breast cancer
Lee, Min Jung
Jung, Ji-Jung
Cheun, Jong-Ho
Kang, Eunhye
Kim, Hong-Kyu
Lee, Han-Byoel
Moon, Hyeong-Gon
Han, Wonshik
BREAST, 2025, 81
[45] The EndoPredict score identifies late distant metastases in ER+/HER2-breast cancer patients
Dubsky, P.
Brase, J. C.
Fisch, K.
Jakesz, R.
Singer, C. F.
Greil, R.
Dietze, O.
Weber, K. E.
Petry, C.
Kronenwett, R.
Rudas, M.
Knauer, M.
Gnant, M.
Filipits, M.
CANCER RESEARCH, 2012, 72
[46] Femara plus ribociclib or placebo as neoadjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer - The Feline trial
Khan, Q. J.
Prochaska, L. H.
Mohammad, J.
Yuan, Y.
O'Dea, A.
Bardia, A.
Wisinski, K.
Hard, M.
Baccaray, S.
Makhoul, I.
Wagner, J.
Laura, S.
Ma, C.
Sharma, P.
CANCER RESEARCH, 2017, 77
[47] Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2− metastatic breast cancer
Kristoffer B. Kristensen
Ida Marie Nedergaard Thomsen
Tobias Berg
Annette R. Kodahl
Anders Bonde Jensen
Breast Cancer Research and Treatment, 2021, 188 : 799 - 809
[48] Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
Ryu, Ho Hyun
Ahn, Sei Hyun
Kim, Seon Ok
Kim, Jeong Eun
Kim, Ji Sun
Ahn, Jin-Hee
Jung, Kyung Hae
Kim, Sung-Bae
Ko, Beom Seok
Lee, Jong Won
Son, Byung Ho
Shin, Hee Jung
Kim, Hak Hee
Gong, Gyung Yub
Kim, Hee Jeong
SCIENTIFIC REPORTS, 2021, 11 (01)
[49] Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
Ho Hyun Ryu
Sei Hyun Ahn
Seon Ok Kim
Jeong Eun Kim
Ji sun Kim
Jin-Hee Ahn
Kyung Hae Jung
Sung-Bae Kim
Beom Seok Ko
Jong Won Lee
Byung Ho Son
Hee Jung Shin
Hak Hee Kim
Gyung yub Gong
Hee Jeong Kim
Scientific Reports, 11
[50] Pathological Complete Response in Neoadjuvant Treatment of Breast Cancer
Patricia Cortazar
Charles E. Geyer
Annals of Surgical Oncology, 2015, 22 : 1441 - 1446

← 1 2 3 4 5 →